Exhaled nitric oxide in asthmatic children exposed to relevant allergens: effect of flunisolide


ABSTRACT: Inhaled corticosteroids are capable of reducing the level of exhaled nitric oxide (expiratory nitric oxide fraction (FE,NO)) in asthmatic patients in a dose-dependent fashion. The aim of this study was to evaluate whether or not treatment with an inhaled steroid can prevent changes in FE,NO after the exposure to relevant allergens, following avoidance, in asthmatic children allergic to house dust mite.

Thirty-two house dust mite-allergy asthmatic children were randomly allocated to treatment with inhaled flunisolide (500 µg b.i.d.) or placebo and evaluated before and after 2 weeks of natural exposure to mite antigens. Lung function and FE,NO were evaluated.

FE,NO increased in the placebo-treated group after antigen exposure. Treatment with inhaled flunisolide prevented such increase in FE,NO (p < 0.001). No change was observed in lung function parameters.

Inhaled flunisolide is effective in preventing the increase in airway inflammation observed in allergic asthmatic children re-exposed to allergens.


It is well recognized that asthma is an inflammatory disease and that indoor allergens, in particular house dust mite, represent a relevant factor in the aetiology of the disease [1]. It has been demonstrated that the development or worsening of asthma symptoms in children may be alleviated by allergen avoidance [2,3] or by suppressing the bronchial response to allergen challenge [4–9].

Recent studies have shown that inhaled corticosteroids are capable of decreasing the FE,NO in asthmatic patients in a dose-dependent fashion [14, 15].

In this study, whether treatment with an inhaled steroid can prevent changes in FE,NO after a brief period of exposure to relevant allergens was evaluated in a group of asthmatic children allergic to house dust mite.

Material and methods

Subjects

Thirty-two children (26 males and six females), ranging in age 6–15 yrs and with a history of bronchial asthma and a positive skin-prick test to house dust mite, were evaluated at the "Istituto Pio XII" long-stay hospital (Misurina, Belluno, Italy), situated at an altitude of 1,756 m in the Italian Alps. None of the patients had had respiratory infections for ≥2 months before the beginning of the study and none of them were allergic to furry pets.

None of the children had received oral corticosteroids for ≥2 months or inhaled corticosteroids for ≥1 month before the study since they were staying in a house dust mite-free environment.

The study was approved by the Istituto Pio XII Ethics Committee and both children and their parents gave informed consent.

Study design

The study was performed between December 1997 and January 1998. The children admitted to the study had been living at the Istituto Pio XII, an environment free of house dust mite allergen because of its location at high altitude, for ≥3 months at the time of admission (t0). The first set of evaluations (t0) was performed immediately before the children left the Istituto Pio XII to spend the Christmas holidays at their family homes, at sea level, and before the first administration of flunisolide. The second set of evaluations (t1) were performed at the time of readmission to the Istituto Pio XII, after the children had been re-exposed to house dust mite allergens for 2 weeks. This study was performed out of the pollen season in order to avoid interference of outdoor allergens for those patients who were also sensitized to pollens.

The evaluations at t0 and t1 consisted of the measurement of pulmonary function and FE,NO. During the study period, symptoms were recorded daily. Patients were randomly divided into two parallel groups of 16 subjects each, receiving either flunisolide (Lunibron A; Valeas, Milan, Italy; 500 µg b.i.d.) or placebo solution in a double-blind fashion. The treatments were started at the time that the children left the residential house and continued during the
time they spent in their parents' houses. Treatments were administered via the same model of nebulizer (Mefar, Bovezzo, Italy), which was provided to all the patients.

Inhaled β₂-agonists were allowed as needed. Neither cromons nor inhaled steroids, other than flunisolide administered in double-blind fashion according to the experimental design, were allowed for the duration of the study.

**Lung function and nitric oxide measurement**

Lung function was measured using a Vitalograph Compact spirometer (Vitalograph, Buckingham, UK). The forced expiratory volume in one second (FEV₁) and forced mid-expiratory flow (FEF₂₅–₇₅) were considered in the analysis of results. The FE(NO) was measured using a chemiluminescence analyser (Logan LR 2149; Logan, Rochester, UK) before performing spirometry [14, 15].

Briefly, the subjects were asked to perform a single slow exhalation starting from total lung capacity through a mouthpiece, against a resistance (mouth pressure >5 cm H₂O) and with biofeedback used to maintain a steady flow of 5 L·min⁻¹. This method allows the separation of the nasopharynx from the oropharynx by the soft palate, hence preventing the contamination of the FE(NO) with nasal NO. This method has been shown to be successfully applicable in both adults and children. The FE(NO) was measured at the plateau of the end-expiratory reading and expressed in parts per billion (ppb) according to guidelines [16]. The FE(NO) considered in the data analysis were always measured at the plateau of FE(NO), taking the plateau of the end-expiratory carbon dioxide reading as representative of an alveolar sample [13, 17].

**Measurement of mite allergen levels**

Parents were asked to collect dust from the mattresses of the subjects participating in the study in a standardized fashion, by vacuuming the mattress surface over an area of ~2 m² for 5 min [18] using a vacuum cleaner containing a new bag. Bags containing samples were stored in a sealed plastic bag at 4°C until the dust was processed for measurement of mite group I allergens, which was performed using monoclonal antibodies in a two-site immunometric enzyme-linked immunosorbent assay (ELISA) [19, 20].

The results were expressed in micrograms of mite group I allergens per gram of dust [21].

**Statistical analysis**

The FE(NO) and lung function (FEV₁ and FEF₂₅–₇₅) evaluated at τ₀ and τ₁ were statistically evaluated using multiple regression analysis [22] of the two regression lines for flunisolide and placebo (τ₀ versus τ₁): the dependent (y) variable is the value measured at τ₁ for each parameter and each patient, whereas the independent (x) variable is the value measured at τ₀. Maximal protection is represented by a slope which is not significantly different from the line of identity, i.e. there were no significant changes in the investigated parameters between τ₀ and τ₁. This was tested by evaluating the following null hypothesis: 1) The parallelism of the two regression lines (flunisolide: y=αF₁+bF₁x; placebo: y=αP₁+bP₁x) to the theoretical line (y=a+bx) with slope (b) equal to 1 and the intercept of the y-axis (a) equal to 0 (line of maximum protection to allergen exposure (LMPAE): y=x), where αF₁ and bF₁ are the a and b for flunisolide and αP₁ and bP₁ are the a and b for placebo, giving bF₁ and bP₁=1. 2) The coincidence of each regression line with the LMPAE (αF₁ or αP₁=0), if the parallelism hypothesis is verified. 3) The coincidence between the two regression lines (αF₁=αP₁), if αF₁ and αP₁≠0. The comparisons were carried out using a t-test utilizing the regression coefficients of the multiple regression model adopted.

Bronchial symptoms were analysed by comparing the sum of a score ranging 0–3 for daytime cough, night-time cough and wheezing using the Mann-Whitney U-test.

**Results**

Of the 32 children who were admitted (table 1), 28 completed the study. One child in the placebo group presented with an upper respiratory tract infection and three in the flunisolide-treated group were not compliant with the scheduled regimen, as verified by checking the personal diary card and evaluating the quantity of unused drug at the end of the study period. These subjects were excluded from the study and therefore the final analysis for the two groups included 15 placebo and 13 flunisolide subjects.

It was possible to obtain dust samples from 25 of the 28 children who completed the study. Four samples, one in the placebo and three in the flunisolide group, were not suitable for analysis because the quantity of dust collected was not sufficient to perform the allergen extraction. The mean level of mite allergen in samples collected in the residential house was 0.04 μg·g⁻¹ dust⁻¹. The levels of house dust mite group I allergens (Der p I and Der f I) were 16.46 μg·g⁻¹ dust⁻¹ in the placebo group and 12.84 μg·g⁻¹ dust⁻¹ in the flunisolide-treated group (NS between treatments and p<0.01 versus level in the residential house).

The individual and mean±SEM FE(NO), FEV₁ and FEF₂₅–₇₅ at τ₀ and τ₁ are shown in figures 1–3. The FE(NO) were comparable in the two groups at τ₀. The results of the multiple regression analysis carried out for FE(NO), FEV₁ and FEF₂₅–₇₅ show that the placebo regression line is not coincident with the LMPAE placebo versus LMPAE, p<0001) for FE(NO). In contrast, a significantly lower FE(NO) was observed in the group treated with flunisolide.
with flunisolide, compared to placebo, after returning to the residential house (flunisolide versus placebo, p < 0.05), suggesting no significant changes in the flunisolide group, and, in addition, no significant difference was observed between the flunisolide regression line and the LMPAE line (flunisolide versus LMPAE, p > 0.05).

When FEV1 and FEF25–75 values are considered, both the placebo and flunisolide regression lines are coincident with the LMPAE (placebo and flunisolide versus LMPAE, p > 0.05).

The mean daily symptom score was 0.72 for the flunisolide-treated group and 1.12 for the placebo treated group (NS).

**Discussion**

It has previously been demonstrated that inhaled corticosteroids are effective in preventing the increase in bronchial reactivity in allergic asthmatic children re-exposed to allergens for 3 months [9].

FeNO has been demonstrated to be more promptly modified by exposure to or avoidance of relevant allergens in allergic asthmatic children [23, 24] than lung function. BARALDI et al. [23] demonstrated that, during the pollen season, FeNO increased significantly in spite of a lack of significant changes in FEV1, and also showed a relatively high FeNO in these patients outside the grass pollen season, in agreement with the hypothesis that mild airway inflammation may persist even in the absence of symptoms [14]. A significant time-dependent modulation of FeNO during house dust mite avoidance has previously been observed in a group of allergic asthmatic children during a stay in the Alpine environment, despite discontinuation of steroid therapy [24].

In the present study, a significant increase in FeNO was observed in the group of patients treated with placebo, but not in those treated with inhaled flunisolide during 2 weeks of exposure to significant levels of mite allergens. In contrast, no difference has been observed between the two treatments in terms of lung function.

This observation is not unexpected since it is known that airway inflammation may be found in asthmatic patients whose lung function values are normal and clinically well controlled [25]. For this reason, it was recently suggested that the monitoring of lung function and symptoms are not sensitive enough to reflect the extent of airway inflammation [25].
The measurement of FE\textsubscript{NO} has been proposed as a simple noninvasive means of monitoring the level of airway inflammation [11–13, 16, 26]. It has also been demonstrated that FE\textsubscript{NO} is increased after allergen-induced asthmatic reactions [27, 28], whereas it is reduced after treatment with inhaled steroids [15] in a dose-related fashion [14]. The present study design represents a natural antigen-induced challenge and the observed changes in FE\textsubscript{NO} in placebo-receiving group suggest that 2 weeks’ exposure to significant amounts of mite allergens can be responsible for an increase in airway inflammation in house dust mite-sensitive asthmatic children.

In this study, a period of treatment before leaving the residential house, aimed at reaching a steady-state steroid effect, was not considered since this could have generated significant differences in baseline FE\textsubscript{NO} between flunisolide and placebo-treated children. However, previous studies have shown that inhaled steroids significantly reduce FE\textsubscript{NO} in placebo-receiving children. However, previous studies have shown that inhaled steroids significantly reduce FE\textsubscript{NO} [14, 15], and, therefore, it is tempting to speculate that the lack of changes in FE\textsubscript{NO} occurred as a result and not In spite of steroid treatment. Therefore, the authors suggest that treatment with inhaled steroid is able to prevent the increase in FE\textsubscript{NO} occurring after a natural allergen challenge.

In conclusion, the expiratory nitric oxide fraction measurement was well accepted by the children who participated in the study, and, from the present results, it is tempting to speculate that expiratory nitric oxide fraction may provide clinical information which would not be revealed by routine lung function testing. Furthermore, by means of this technique, it has been demonstrated that inhaled flunisolide is effective in preventing the increase in airway inflammation in allergic asthmatic children re-exposed to allergens, even if, from this study, it is not possible to reach firm conclusions regarding the clinical significance of an increase in expiratory nitric oxide fraction in the absence of measurements of lung function or symptoms.

Acknowledgements. The authors wish to thank M. Fano (Valeas, Milan, Italy) for the statistical analysis and Valeas for providing flunisolide and the nitric oxide analyser.

References


